GlobeNewswire by notified

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer

Share
  • The SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival
  • The other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysis
  • The tiragolumab development programme continues as planned in non-small cell lung cancer and other cancer types

Basel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). The study did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival (OS) was immature, and the study will continue until the next planned analysis. A numerical improvement was observed in both co-primary endpoints. Data suggest that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab. Further analyses of these results are ongoing and data will be presented at an upcoming medical meeting.

“While these results are not what we hoped for in our first analysis, we look forward to seeing mature overall survival for this study to determine next steps,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We continue to believe that TIGIT may have a role in cancer treatment and we will share additional results from our tiragolumab programme as they emerge.”

The tiragolumab programme continues to explore advances in multiple clinical trials to build on Tecentriq, expand into earlier stages of disease, and seeks to provide new treatment options in advanced and difficult-to-treat cancers with high unmet medical need.

About the SKYSCRAPER-01 study
SKYSCRAPER-01 is a global phase III, randomised double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone in 534 patients with first-line PD-L1-high locally advanced, unresectable or metastatic non-small cell lung cancer. Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit or unacceptable toxicity. Co-primary endpoints are overall survival and progression-free survival.

About tiragolumab
Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer.1 Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab).2 The TIGIT pathway is distinct but complementary to the PD-L1/PD-1 pathway. Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response.1

About Tecentriq® (atezolizumab)
Tecentriq is a cancer immunotherapy approved for some of the most aggressive and difficult-to-treat forms of cancer. Tecentriq was the first cancer immunotherapy approved for the treatment of a certain type of early-stage (adjuvant) non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and hepatocellular carcinoma. Tecentriq is also approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, certain types of metastatic urothelial cancer, PD-L1-positive metastatic triple-negative breast cancer and BRAF V600 mutation-positive advanced melanoma.

Tecentriq is a monoclonal antibody designed to bind with a protein called programmed death ligand-1 (PD-L1), which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells. Tecentriq is a cancer immunotherapy that has the potential to be used as a foundational combination partner with other immunotherapies, targeted therapies and various chemotherapies across a broad range of cancers. In addition to intravenous infusion, the formulation of Tecentriq is also being investigated as subcutaneous injection to hopefully provide a faster and more convenient option for cancer patients.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Cho BC, Rodriguez-Abreu D, et al. Updated analysis and patient-reported outcomes from CITYSCAPE: a randomised, double-blind, Phase II study of the anti-TIGIT antibody tiragolumab + atezolizumab vs placebo + atezolizumab as first-line treatment for PD-L1+ NSCLC. Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021; 2021 December 8-11. Abstract #LBA2.
[2] Johnston RJ, Comps-Agrar L. Cancer Cell. 2014;26:923-937.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 61 687 41 47
SileiaUrech
Phone: +41 79 935 81 48

Barbara von Schnurbein, PhD
Phone: +41 61 687 89 67
KarstenKleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05

Roche Investor Relations

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 202224.5.2022 22:05:00 CEST | Press release

ERYTECHAnnounces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 Cambridge, MA (U.S.) and Lyon (France), May 24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the availability of the documents for its Annual General Meeting to be held on Friday, June 24, 2022. ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2 rue Scribe, 75009 Paris (FRANCE). Shareholders may participate in the General Meeting as follows: Attend in person; Voting by mail or by internet on the secure voting platform Votaccess; or Give a proxy to any individual or legal entity of their choice, under the applicable legal and regulatory conditions, or give a proxy to the Chairman of the Shareholde

Data Quality Leaders Unite Around Alation’s ‘Open Data Quality Initiative’24.5.2022 16:50:06 CEST | Press release

Alation 2022.2 includes new framework that drives freedom of choice and flexibility for organisations; delivers quality data to data consumers at point of consumption REDWOOD CITY, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Alation Inc., the leader in enterprise data intelligence solutions, announced that leading data quality and data observability providers such as Acceldata, Anomalo, Bigeye, Experian, FirstEigen, Lightup, and Soda, and industry partners including Capgemini and Fivetran, have joined Alation in support of its newly launched Alation Open Data Quality Initiative for the Modern Data Stack. The program provides customers with the freedom of choice and flexibility when selecting the best data quality and data observability vendors to fit the needs of their modern, data-driven organisations. The Open Data Quality Initiative was designed to accelerate data governance and access to trusted self-service analytics for the broadest range of data consumers. Data quality is a top pri

PubMatic Launches Connect to Streamline Data Activation on the Sell-Side24.5.2022 16:00:00 CEST | Press release

New Fully Integrated, Omnichannel Addressability Solution Helps Buyers Target Audiences with Any Data Currency NO-HEADQUARTERS/REDWOOD CITY, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- PubMatic (Nasdaq: PUBM), an independent technology company delivering digital advertising’s supply chain of the future, today announced the launch of Connect, a comprehensive and fully integrated platform to enable media buyers to seamlessly connect with their target audiences across the open internet. Connect is one of the only unbiased addressability offerings that combines many of the preferred signal approaches into one platform, including known identity, first- and second-party data, contextual signals, seller-defined audiences, and modeled audiences. The solution enables brands and media buyers to activate a portfolio approach to addressability to improve ad relevance while respecting consumer privacy, well ahead of the ecosystem's transition away from the third-party cookie. Connect builds on the mom

JETEX AND VOLOCOPTER REVOLUTIONIZE URBAN AIR MOBILITY MODEL24.5.2022 15:20:31 CEST | Press release

At EBACE 2022, Jetex and Volocopter sign a milestone strategic partnership agreement to define a safe and sustainable model of urban air mobility (UAM) Dubai, United Arab Emirates, May 24, 2022 (GLOBE NEWSWIRE) -- Jetex, an award-winning leader in private aviation, and Volocopter, a pioneer in the world’s first-ever eVTOL suite of services, enter in a strategic partnership agreement to deploy and operate permanent, economically sustainable, and integrated UAM taxi take-off and landing infrastructure and services for passenger transportation. Recent technological advancements and the need for more affordable, rapid and sustainable travel are driving this trend forward. Both companies aim to launch operations from 2024. Miami, Singapore and Paris are the priority markets where Jetex already established its presence and where sustainable air taxi operations are being mapped for passenger transportation. Jetex and Volocopter are researching most popular routes in these markets to ensure se

Auriant Mining:s delårsrapport för Q1 2022 och online-konferens den 31 maj 202224.5.2022 15:20:21 CEST | Pressemelding

Auriant Mining AB har nöjet att meddela att Bolagets delårsrapport för Q1 2022 kommer att publiceras på tisdagen den 31 maj. Detta kommer att följas av ZOOM-konferens för analytiker och investerare med Danilo Lange (VD), Vladimir Vorushkin (Ekonomichef) and Petr Kustikov (Operativ chef), som kommer att presentera Auriant Mining:s resultat för Q1 2022 samt med en möjlighet att ställa frågor. Evenemanget börjar kl. 13:00 CET (13:00 Stockholm, 14:00 Moskva, 12:00 London). För att delta i ZOOM-konferensen tisdagen den 31 maj, vänligen skicka till e-post conf@auriant.com följande uppgifter: e-post, namn, företagsnamn. Vi kommer att skicka konferens-ID och lösenord via mail. Om du har några frågor kan du skicka dem till e-post: conf@auriant.com För mer information, vänligen kontakta: Danilo Lange, VD Tel: +7 495 109 02 82 E-post: d.lange@auriant.com Företagsnamn: Auriant Mining AB Kortnamn: AUR ISIN-kod: SE0001337213 Webbplats: www.auriant.com Auriant Mining AB (AUR) är ett svenskt gruvbolag